头颈部血管瘤和脉管畸形研究回顾与展望

摘要/Abstract

摘要： [提要] 血管瘤和脉管畸形是常见于头颈部的一组疾病,其发病机制尚不明确。虽然近10多年来血管瘤和脉管畸形的学术交流不断加强,新的治疗理念与技术引进,使许多复杂、疑难病例在多学科协作下取得较好的疗效,但由于病变的部位、临床表现或就诊年龄不同,患者可能在不同的科室诊治,使用不规范术语或不合理治疗的现象仍然存在。弥散性脉管畸形难以治愈,常需综合治疗。作者结合国内外文献,简要介绍血管瘤和脉管畸形的新分类、现代治疗策略,并回顾相关学术活动、取得的研究成果,提出此领域仍存在的相关问题及面临的挑战。

关键词: 血管瘤, 脉管畸形, 头颈部

Abstract: [Summary] Infantile hemangioma and vascular malformations are a spectrum of disorders commonly involving the head and neck regions, and their pathogenesis remains poorly understood. Owing to increased academic exchange,introduction of new therapeutic strategies and emerging treatment techniques during the last decade, many complicated vascular malformations are cured or obviously improved by multidisciplinary approach. However, outdated terminology and/or improper management are sometimes used because of diversities of clinical presentation and locations of lesions,age at diagnosis and doctor's experience. Diffuse venous malformations or microcystic lymphatic malformations usually are managed by combined modalities, and surgical resection would lead to poor post-surgical outcomes with a high incidence of complications and recurrences. This paper reviewed the contemporary classification and treatment paradigms, academic activities and achievements in the investigation of vascular anomalies in China, with discussing of up-to-date diagnosis and treatment, and possible perspectives were proposed as well.

Key words: Hemangioma, Vascular malformations, Head and neck

中图分类号:

R739.8

赵怡芳, 贾俊. 头颈部血管瘤和脉管畸形研究回顾与展望[J]. 中国口腔颌面外科杂志, 2016, 14(4): 289-301.

ZHAO Yi-fang, JIA JUN. Review and perspectives of study of hemangiomas and vascular malformations in the head and neck[J]. China J Oral Maxillofac Surg, 2016, 14(4): 289-301.

参考文献

[1] Mccarthy J. Plastic Surgery. Volume 5：Tumors of the Head, Neck, and Skin [M]. Philadelphia: WB Saunders Company, 1990.
[2] Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics [J]. Plast Reconstr Surg, 1982, 69(3): 412-422.
[3] Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck [M]. New York: Wiley-liss, 1999.
[4] Enjolras O, Mulliken J. Vascular tumors and vascular malformations (new issues) [J]. Adv Dermatol, 1997, 13(13): 375-423.
[5] 贾玉林, 赵怡芳, 张文峰. 口腔颌面部血管瘤和脉管畸形的分类 [J]. 临床口腔医学杂志, 2002, 18(4): 312-313.
[6] 邱蔚六. 口腔颌面外科学 [M]. 第5版. 北京: 人民卫生出版社, 2006: 251-255.
[7] Sangueza OP, Kasper RC, Leboit P, et al. Pathology and genetics of skin tumors: World Health Organization classification of tumours [M]. 10 Ed. Lyon: IARC, 2006: 233-246.
[8] Fletcher CDM. WHO classification of tumours of soft tissue and bone [M]. 4 Ed. Lyon: IARC Press, 2013: 138-140.
[9] Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies [J]. Pediatrics, 2015, 136(1): e203-214.
[10] 郑家伟, 张凌, 陈正岗. 脉管异常的ISSVA新分类 [J]. 中国口腔颌面外科杂志, 2015, 13(5): 385-388.
[11] Blatt J, Powell CM, Burkhart CN, et al. Genetics of hemangiomas, vascular malformations, and primary lymphedema [J]. J Pediatr Hematol Oncol, 2014, 36(8): 587-593.
[12] North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas [J]. Hum Path, 2000, 31(1): 11-22.
[13] Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy [J]. Pediatrics, 2013, 131(1): 99-108.
[14] Greenberger S, Bischoff J. Pathogenesis of infantile haemangioma [J]. Br J Dermatol, 2013, 169(1): 12-19.
[15] Walter JW, Blei F, Anderson JL, et al. Genetic mapping of a novel familial form of infantile hemangioma [J]. Am J Med Genet, 1999, 82(1): 77-83..
[16] Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma [J]. Genes Chromosomes Cancer, 2002, 33(3): 295-303.
[17] Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma [J]. Nat Med, 2008, 14(11): 1236-1246.
[18] Pramanik K, Chun CZ, Garnaas MK, et al. Dusp-5 and Snrk-1 coordinately function during vascular development and disease [J]. Blood, 2009, 113(5): 1184-1191.
[19] Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood [J]. J Clin Invest, 1994, 93(6): 2357-2364.
[20] Hasan Q, Roger BM, Tan ST, et al. Clusterin/apoJ expression during the development of hemangioma [J]. Hum Path, 2000, 31(6): 691-697.
[21] Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations [J]. Am J Hum Genet, 2003, 73(6): 1240-1249.
[22] Vikkula M, Boon LM, Carraway KL 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2 [J]. Cell, 1996, 87(7): 1181-1190.
[23] Nguyen HL, Boon LM, Vikkula M. Genetics of vascular malformations [J]. Semin Pediatr Surg, 2014, 23(4): 221-226.
[24] Limaye N, Wouters V, Tuominen M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations [J]. Nat Genet, 2009, 41(1): 118-124.
[25] Revencu N, Boon LM, Mendola A, et al. RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation [J]. Hum Mutat, 2013, 34(12): 1632-1641.
[26] Longy M, Coulon V, Dubou B, et al. Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype [J]. J Med Genet, 1998, 35(11): 886-889.
[27] Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies [J]. J Clin Invest, 2014, 124(3): 898-904.
[28] Osborn AJ, Peter D, Neilson DE, et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations [J]. Hum Mol Genet, 2015, 24(4): 926-938.
[29] Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA [J]. J Pediatr, 2015, 166(4): 1048-1054.
[30] Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants [J]. Arch Dis Child Fetal Neonatal Ed, 2015, 100(1): F85-91.
[31] 张志愿, 赵怡芳, 郑家伟. 头颈部血管瘤与脉管畸形 [M]. 上海: 世界图书出版公司上海公司, 2007: 1-5, 119-123.
[32] Bauland CG, Lning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions [J]. Plast Reconstr Surg, 2011, 127(4): 1643-1648.
[33] Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group [J]. Eur J Pediatr, 2015, 174(7): 855-865.
[34] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组. 口腔颌面部血管瘤治疗指南[J]. 中国口腔颌面外科杂志, 2011, 9(1): 61-67.
[35] 郑家伟, 王延安, 周国瑜, 等. 头颈部血管瘤治疗适应证的探讨 [J]. 上海口腔医学, 2007, 16(4): 337-342.
[36] 沈时岳, 邬腊梅, 杨宏宇, 等. 小剂量平阳霉素早期干预婴幼儿腮腺血管瘤疗效分析 [J]. 中国口腔颌面外科杂志, 2013, 11(4): 340-344.
[37] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. New Engl J Med, 2008, 358(24): 2649-2651.
[38] 秦中平, 刘学键, 李克雷, 等. 小剂量普萘洛尔口服治疗婴儿血管瘤的近期疗效与安全性评价[J]. 中华医学杂志, 2009, 89(44): 3130-3134.
[39] 宇文婷, 梁衍灿, 陈伟良, 等. 普萘洛尔治疗婴幼儿血管瘤53例近期疗效分析[J]. 中国口腔颌面外科杂志, 2013, 11(5): 407-411.
[40] Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma [J]. N Engl J Med, 2015, 372(8): 735-746.
[41] Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review [J]. Pediatr Dermatol, 2013, 30(2): 182-191.
[42] Andersen IG, Rechnitzer C, Charabi B. Effectiveness of propranolol for treatment of infantile haemangioma [J]. Dan Med J, 2014, 61(2): A4776.
[43] Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference [J]. Pediatr, 2013, 131(1): 128-140.
[44] 王维, 林晓曦, 马刚, 等. 脉冲染料激光治疗微静脉畸形的自身对照研究 [J]. 组织工程与重建外科杂志, 2010, 6(5): 272-275.
[45] Liu X, Fan Y, Huang J, et al. Can we predict the outcome of 595-nm wavelength pulsed dye laser therapy on capillary vascular malformations from the first beginning: a pilot study of efficacy co-related factors in 686 Chinese patients [J]. Lasers Med Sci, 2015, 30(3): 1041-1046.
[46] 周国瑜, 沈玲悦, 赵婷婷, 等. 微静脉畸形激光治疗研究现状与进展 [J]. 中国实用口腔科杂志, 2009, 2(5): 268-271.
[47] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组. 口腔颌面-头颈部静脉畸形诊治指南 [J]. 中国口腔颌面外科杂志, 2011, 9(6): 510-517.
[48] 赵怡芳. 血管瘤与脉管畸形的药物治疗[J]. 口腔颌面外科杂志, 2003, 13(2): 153-155.
[49] 张森林, 寿柏泉. 口腔颌面部静脉畸形1412例临床报告 [J]. 临床口腔医学杂志, 2005, 21(3): 181-182.
[50] Stimpson R, Hewitt R, Barnacle A, et al. Sodium tetradecyl sulphate sclerotherapy for treating venous malformations of the oral and pharyngeal regions in children [J]. Int J Pediatr Otorhinolaryngol, 2012, 76(4): 569-573.
[51] Zhao JH, Zhang WF, Zhao YF. Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate [J]. Int J Oral Maxillofac Surg, 2004, 33(5): 463-466.
[52] 杨耀武, 孙沫逸, 吕菊红, 等. 纤维蛋白胶复合平阳霉素栓塞硬化治疗口腔颌面部静脉畸形 [J]. 实用口腔医学杂志, 2008, 24(2): 209-212.
[53] 王延安, 郑家伟, 张志愿, 等. 无水乙醇硬化治疗头颈部静脉畸形的并发症及其预防[J]. 中国口腔颌面外科杂志, 2009, 7(5): 389-391.
[54] Lei ZM, Huang XX, Sun ZJ, et al. Surgery of lymphatic malformations in oral and cervicofacial regions in children [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 104(3): 338-344.
[55] 赵福运. 头颈部血管瘤与脉管畸形 [M]. 北京: 科学技术文献出版社, 2010: 127-137.
[56] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组. 口腔颌面部淋巴管畸形治疗指南 [J]. 中国口腔颌面外科杂志, 2010, 8(5): 386-390.
[57] Smith MC, Zimmerman MB, Burke DK, et al. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations [J]. Laryngoscope, 2009, 119(1): 107-115.
[58] Yang Y, Sun M, Ma Q, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations [J]. J Vasc Surg, 2011, 53(1): 150-155.
[59] Shergill A, John P, Amaral JG. Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy [J]. Pediatr Radiol, 2012, 42(9): 1080-1088.
[60] 范晶, 王立丹, 黄穗, 等. 聚桂醇泡沫硬化剂治疗儿童头颈部大囊型淋巴管畸形疗效研究[J]. 临床放射学杂志, 2014, 33(9): 1412-1415.
[61] Bai Y, Jia J, Huang XX, et al. Sclerotherapy of microcystic lymphatic lalformations in oral and facial regions [J]. J Oral Maxillofac Surg, 2009, 67(2): 251-256.
[62] 赵怡芳, 赵吉宏. 淋巴管畸形的治疗 [J]. 中国实用口腔科杂志, 2009, 2(5): 271-274.
[63] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组. 口颌面部动静脉畸形诊治指南[J]. 中国口腔颌面外科杂志, 2011, 9(3): 242-247.
[64] 范新东. 颅面部介入诊疗学[M]. 上海: 世界图书出版上海有限公司, 2011: 35-39.
[65] 范新东, 朱凌, 苏立新. 颞浅动脉逆行栓塞治疗颈外动脉结扎后的口腔颌面部动-静脉畸形探讨[J]. 中华口腔医学杂志, 2008, 43(6): 336-338.
[66] Do YS, Yakes WF, Shin SW, et al. Ethanol embolization of arteriovenous malformations: interim results [J]. Radiology, 2005, 235(2): 674-682.
[67] 金云波, 林晓曦, 胡晓洁, 等. DSA下无水乙醇超选择性血管内治疗颅面部动静脉畸形[J]. 中华整形外科杂志, 2009, 25(6): 406-411.
[68] Su L, Wang D, Han Y, et al. Absolute ethanol embolization of infiltrating-diffuse extracranial arteriovenous malformations in the head and neck [J]. Eur J Vasc Endovasc Surg, 2015, 50(1): 114-121.
[69] 范新东, 邱蔚六, 张志愿, 等. “双介入法”栓塞治疗颌骨动静脉畸形的初步报告 [J].中华口腔医学杂志, 2002, 37(5): 336-339.
[70] Fan XD, Su LX, Zheng JW, et al. Ethanol embolization of the arteriovenous malformation in the mandible [J]. AJNR Am J Neuroradiol, 2009, 30(6): 1178-1183.
[71] 郑家伟, 张志愿, 郑苍尚, 等. 2004'全国口腔颌面部脉管性疾病学术研讨会纪要[J]. 中国口腔颌面外科杂志, 2004, 2(3): 355-356.
[72] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组. 口腔颌面部血管瘤及脉管畸形的诊断和治疗指南(草案) [J]. 中华口腔医学杂志, 2005, 40(3): 185-186.
[73] 张志愿. 口腔颌面部脉管性疾病: 过去、现在和将来 [J]. 中华口腔医学杂志, 2005, 40(3): 177-181.
[74] 郑家伟, 张志愿. 2005年口腔颌面部静脉、淋巴管畸形治疗专题研讨会会议纪要 [J]. 中华口腔医学杂志, 2005, 40(6): 450.
[75] 陈传俊, 郑家伟. 2007 年第四届全国口腔颌面部脉管性疾病学术研讨会会议纪要[J]. 中国口腔颌面外科杂志, 2007, 5(4): 445.
[76] 郑连洲, 范新东, 郑家伟. 无水乙醇栓塞治疗颅面部动静脉畸形的现状与进展 [J]. 中国口腔颌面外科杂志, 2009, 7(3): 276-280.
[77] 张伟, 何克飞, 朱钧一, 等. 中国脉管性疾病研究文献分析 [J]. 国际口腔医学杂志, 2015, 42(6): 647-651.
[78] Hassanein AH, Mulliken JB, Fishman SJ, et al. Evaluation of terminology for vascular anomalies in current literature [J]. Plast Reconstr Surg, 2011, 127(1): 347-351.
[79] 郭小科, 张伟, 赵怡芳. 国家自然科学基金资助体表脉管性疾病项目和发表论文分析[J]. 口腔医学研究, 2015, 31(z3): 39-41.
[80] Zheng JW, Zhou Q, Yang XJ, et al. Treatment guideline for hemangiomas and vascular malformations of the head and neck [J]. Head Neck, 2010, 32(8): 1088-1098.
[81] Zhou Q, Zheng JW, Mai HM, et al. Treatment guidelines of lymphatic malformations of the head and neck [J]. Oral Oncol, 2011, 47(12): 1105-1109.
[82] 邱蔚六. 新的五年, 新的挑战—我国口腔颌面-头颈肿瘤外科发展之我见 [J]. 中华口腔医学杂志, 2006, 41(8): 449-552.
[83] McCafferty I. Management of low-flow vascular malformations: clinical presentation, classification, patient selection, imaging and treatment[J]. Cardiovasc Intervent Radiol, 2015, 38(5): 1082-1104.
[84] van der Vleuten CJ, Kater A, Wijnen MH, et al. Effectiveness of sclerotherapy, surgery, and laser therapy in patients with venous malformations: a systematic review[J]. Cardiovasc Intervent Radiol, 2014, 37(4): 977-989.
[85] Blatt J, Mclean TW, Castellino SM, et al. A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations [J]. Pharmacol Ther, 2013, 139(3): 327-333.
[86] Spence J, Krings T, TerBrugge KG, et al. Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy[J]. Head Neck,2011,33(1):125-130.
[87] Caussé S, Aubert H, Saint-Jean M, et al. Propranolol-resistant infantile hemangiomas [J]. Br J Dermatol, 2013, 169(1): 125-129.
[88] 孙桦梁, 席善龙, 魏景健, 等. 普萘洛尔联合低剂量泼尼松治疗普萘洛尔耐药性血管瘤的近期疗效观察 [J].中国口腔颌面外科杂志, 2013, 11(4): 334-338.
[89] Malik MA, Menon P, Rao KL, et al. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study[J]. J Pediatr Surg, 2013, 48(12): 2453-2459.
[90] Aly MM, Hamza AF, Abdel Kader HM, et al. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma[J]. Eur J Pediatr, 2015, 174(11): 1503-1509.
[91] Lamy S, Lachambre MP, Lord-Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells[J]. Vascul Pharmacol, 2010, 53(5-6): 200-208.
[92] Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(2): 269-274.
[93] Greenberger S, Bischoff J. Infantile hemangioma-mechanism (s) of drug action on a vascular tumor [J]. Cold Spring Harb Perspect Med, 2011, 1(1): a006460.
[94] Wong A, Hardy KL, Kitajewski AM, et al. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells [J]. Plast Reconstr Surg, 2012, 130(5): 1012-1021.
[95] Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis [J]. Exp Ther Med, 2012, 4(4): 594-604.
[96] Zou HX, Jia J, Zhang WF, et al. Propranolol inhibits endothelial progenitor cell homing: a possible treatment mechanism of infantile hemangioma [J]. Cardiovas Path, 2013, 22(3): 203-210.
[97] Kum JJ, Khan ZA. Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis [J]. Pediatr Res, 2013, 75(3): 381-388.
[98] 赵怡芳, 贾俊. 低剂量普萘洛尔联合低剂量泼尼松治疗血管瘤: 一种新的治疗选择[J]. 中国口腔颌面外科杂志, 2013, 11(4): 338-339.
[99] Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas [J]. Br J Dermatol, 2015, 172(1): 13-23.
[100] de Graaf M, Raphael MF, Breugem CC, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group[J]. J Plast Reconstr Aesthet Surg, 2013, 66(12): 1732-1740.
[101] Yakes WF, Luethke JM, Parker SH, et al. Ethanol embolization of vascular malformations [J]. Radiographics, 1990, 10(5): 787-796.
[102] Bisdorff A, Mazighi M, Saint-Maurice JP, et al. Ethanol threshold doses for systemic complications during sclerotherapy of superficial venous malformations: a retrospective study [J]. Neuroradiology, 2011, 53(11): 891-894.
[103] Schumacher M, Dupuy P, Bartoli JM, et al. Treatment of venous malformations: first experience with a new sclerosing agent-a multicenter study [J]. Eur J Radiol, 2011, 80(3): e366-372.
[104] Ren J, Wang H, Chen G, et al. In vivo synergetic effect of in situ sclerotherapy and transient embolotherapy designed for fast-flow vascular malformation treatments with the aid of injectable hydrogel [J]. J Mater Chem B, 2013, 1(20): 2601-2611.
[105] 徐骎, 张志愿, 陈万涛, 等. 转基因小鼠血管瘤动物模型建立 [J]. 中华口腔医学杂志, 2003, 38(5): 355-357.
[106] Tang Y, Liu W, Yu S, et al. A novel in vivo model of human hemangioma: xenograft of human hemangioma tissue on nude mice [J]. Plast Reconstr Surg, 2007, 120(4): 869-878.
[107] 刘超, 秦中平, 魏奉才, 等. 细胞注射法和组织块移植法在构建血管瘤动物模型中的比较[J]. 山东大学学报: 医学版, 2012, 50(5): 46-50.
[108] 麦华明, 郑家伟. 血管瘤动物模型的研究进展 [J]. 组织工程与重建外科杂志, 2010, 6(2): 114-117.
[109] Sun Y, Jia J, Zhang W, et al. A reproducible in-vivo model of lymphatic malformation in rats[J]. J Compar Path, 2011, 145(4): 390-398.
[110] Wang YA, Zheng JW, Fei ZL, et al. A novel transgenic mice model for venous malformation[J]. Transgenic Res, 2009, 18(2): 193-201.
[111] Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice [J]. J Clin Invest, 2008, 118(7): 2592-2599.
[112] Zhang W, Chen G, Wang FQ, et al. Macrophages contribute to the progression of infantile hemangioma by regulating the proliferation and differentiation of hemangioma stem cells [J]. J Invest Dermatol, 2015, 135(12): 3163-3172.
[113] Boscolo E, Limaye N, Huang L, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects [J]. J Clin Invest, 2015, 125(9): 3491-3504.
[114] Lokmic Z, Mitchell GM, Koh Wee Chong N, et al. Isolation of human lymphatic malformation endothelial cells, their in vitro characterization and in vivo survival in a mouse xenograft model [J]. Angiogenesis, 2014, 17(1): 1-15.
[115] Wu JK, Kitajewski C, Reiley M, et al. Aberrant lymphatic endothelial progenitors in lymphatic malformation development [J]. PLoS One, 2015, 10(2): e0117352.